SCHEMBL5148967

SCHEMBL5148967

CC(C)n1nc(-c2nc(OCCCc3ccccc3)c(N)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.36
SRC P12931 3/20 0.36
ABL1 P00519 2/20 0.36
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA3 P34903 1/20 0.36
PDE4A P27815 3/20 0.36
PDE4B Q07343 3/20 0.36
PDE4C Q08493 3/20 0.36
PDE4D Q08499 3/20 0.36
DHFR P00374 1/20 0.36
FGFR1 P11362 4/20 0.35
FGFR2 P21802 4/20 0.35
FGFR3 P22607 4/20 0.35
TLR8 Q9NR97 1/20 0.35
TLR7 Q9NYK1 1/20 0.35
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
PIK3CD O00329 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5148946 0.96 SMN1; SMN2 (0.37) HRH3SRCABL1GABRA1GABRG2
SCHEMBL5149212 0.91 SRC (0.40) HRH3SRCABL1DHFRFGFR1
SCHEMBL5152714 0.91 SRC (0.38) HRH3SRCABL1PDE4DFGFR1
SCHEMBL5149200 0.90 SRC (0.43) SRCABL1FGFR1FGFR2FGFR3
SCHEMBL5149085 0.90 SRC (0.38) HRH3SRCABL1FGFR1FGFR2
SCHEMBL5152824 0.89 MPO (0.38) HRH3SRCABL1FGFR1FGFR2
SCHEMBL5152823 0.87 ADORA2A (0.41) HRH3FGFR1FGFR2FGFR3ADORA2A
SCHEMBL5152617 0.87 PKM (0.41) HRH3GABRA1GABRG2GABRB3GABRA3
SCHEMBL5147947 0.87 HRH3 (0.34) HRH3SRCABL1FGFR1FGFR2
SCHEMBL5150959 0.84 FGFR1 (0.39) SRCABL1FGFR1FGFR2FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US disclosed
CN-1938296-A Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists ASTELLAS PHARMA INC (JP) 2007-03-28 CN disclosed
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, HTR5A, ADORA1 HRH3 43/4885SRC 1884/4885ABL1 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.